一种用于测量膀胱过度活动症女性对抗胆碱能药物依从性的自我管理工具的验证。
Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.
作者信息
Andy Uduak U, Harvie Heidi S, Smith Ariana L, Propert Kathleen J, Bogner Hillary R, Arya Lily A
机构信息
Division of Urogynecology, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Division of Urology, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
出版信息
Neurourol Urodyn. 2015 Jun;34(5):424-8. doi: 10.1002/nau.22605. Epub 2014 Apr 9.
AIM
To validate a self-administered instrument, the Medication Adherence Self-Report Inventory (MASRI) for measuring adherence to anti-cholinergic medication for overactive bladder (OAB).
METHODS
Prospective study in 131 women with OAB treated with fesoterodine. Adherence was measured at 8 and 12 weeks using an interviewer administered brief medication questionnaire (BMQ) that assesses barriers to adherence (criterion standard), the MASRI, and pill count. Construct, concurrent and discriminant validity of the MASRI was assessed. We hypothesized that women who were non-adherent as measured by the MASRI would be more likely to have a belief barrier than women who were adherent to medication.
RESULTS
Women diagnosed as non-adherent by the MASRI were more likely to report a belief barrier to taking medication as compared to adherent women at 8 weeks (80% vs. 38%, P < 0.001) and at 12 weeks (70% vs. 40%, P = 0.003). Significant correlations were noted between adherence rates measured by the MASRI and the BMQ at 8 weeks (r = 0.87, P < 0.001) and 12 weeks (r = 0.90, P < 0.001). Moderate correlation was noted between the adherence rate as measured by the MASRI and pill count at 8 weeks (r = 0.49, P = 0.02) but not at 12 weeks (r = 0.05, P = 0.87). The MASRI correctly identified 93% and 96% of non-adherent women at 8 and 12 weeks, respectively. Sensitivity, specificity, and positive likelihood ratio of the MASRI for predicting non-adherence was 91%, 82%, and 5.1 at 8 weeks and 90%, 85% and 6.1 at 12 weeks.
CONCLUSIONS
The MASRI is a valid self-administered tool for measuring adherence to anti-cholinergic medication in women with OAB.
目的
验证一种自我管理工具——药物依从性自我报告量表（MASRI），用于测量膀胱过度活动症（OAB）患者对抗胆碱能药物的依从性。
方法
对131名接受非索罗定治疗的OAB女性患者进行前瞻性研究。在第8周和第12周时，使用由访视者实施的简短药物问卷（BMQ）来测量依从性，该问卷评估依从性的障碍（标准对照）、MASRI以及药片计数。评估了MASRI的结构效度、同时效度和区分效度。我们假设，通过MASRI测量为不依从的女性比依从药物治疗的女性更有可能存在信念障碍。
结果
与依从的女性相比，在第8周（80%对38%，P<0.001）和第12周（70%对40%，P=0.003）时，被MASRI诊断为不依从的女性更有可能报告服药存在信念障碍。在第8周（r=0.87，P<0.001）和第12周（r=0.90，P<0.001）时，MASRI测量的依从率与BMQ之间存在显著相关性。在第8周时，MASRI测量的依从率与药片计数之间存在中度相关性（r=0.49，P=0.02），但在第12周时不存在相关性（r=0.05，P=0.87）。MASRI在第8周和第12周时分别正确识别出93%和96%的不依从女性。MASRI预测不依从的敏感性、特异性和阳性似然比在第8周时分别为91%、82%和5.1，在第12周时分别为90%、85%和6.
Zotero 插件